Pending Drug Applications To Be Poussot’s Top Priority As Wyeth’s New CEO
This article was originally published in The Pink Sheet Daily
Firm announces third quarter pharmaceutical earnings of $4.7 billion, up 10 percent year-over-year.
You may also be interested in...
Long-time Wyeth exec Bernard Poussot will replace Robert Essner effective Jan. 1.
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.
Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.